Alchemab Therapeutics

Alchemab Therapeutics Ltd is a biopharmaceutical company based in London, UK, founded in 2019. The company focuses on discovering and developing therapeutic antibodies derived from resilient individuals to address hard-to-treat diseases, particularly those that lack effective treatments. Alchemab has raised over $80 million from various investors, including SV Health Investors and Eli Lilly and Company. The company utilizes a unique platform that combines data mining and machine learning to analyze immune responses from individuals who have successfully resisted diseases like cancer. This approach allows Alchemab to identify novel antibodies and develop them into therapies. Their lead program, ATLX-1282, is an IND-ready antibody targeting a new receptor for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. This program has been licensed to Eli Lilly, which is advancing it clinically.